Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Scientists transformed energy-storing white fat cells into calorie-burning 'beige' fat. Once implanted, they outcompeted tumors for resources, beating back five different types of cancer in lab ...

But it’s a slippery slope. When does reducing the risk of inherited breast cancer, diabetes, or Alzheimer’s disease edge into “designer baby” territory? As scientists grapple with the implications of ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

Furthermore, Crispr Therapeutics is expanding its studies in autoimmune disorders and Type 1 Diabetes, with anticipated updates that could diversify and strengthen its therapeutic portfolio.

CRISPR Therapeutics is developing CTX112 for ... including the clinical trial for CTX211™ in Type 1 diabetes (T1D) and subsequent next generation programs. These programs focus on allogeneic ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...